Symbols / CTNM Stock $12.54 -3.32% Contineum Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
CTNM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Carmine N. Stengone MBA, MS
Exch · Country NMS · United States
Market Cap 468.19M
Enterprise Value 213.55M
Income -59.98M
Sales —
FCF (ttm) -36.92M
Book/sh 6.99
Cash/sh 7.04
Employees 51
Insider 10d —
IPO Apr 05, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.77
PEG —
P/S —
P/B 1.79
P/C —
EV/EBITDA -3.15
EV/Sales —
Quick Ratio 26.98
Current Ratio 27.50
Debt/Eq 3.16
LT Debt/Eq —
EPS (ttm) -2.17
EPS next Y -2.17
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-05
ROA -17.38%
ROE -26.13%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 32.67M
Shs Float 25.36M
Insider Own 1.00%
Instit Own 93.32%
Short Float 10.16%
Short Ratio 8.40
Short Interest 3.10M
52W High 16.33
vs 52W High -23.21%
52W Low 3.35
vs 52W Low 274.33%
Beta 1.39
Impl. Vol. —
Rel Volume 0.54
Avg Volume 288.00K
Volume 155.59K
Target (mean) $22.00
Tgt Median $21.50
Tgt Low $14.00
Tgt High $29.00
# Analysts 6
Recom None
Prev Close $12.97
Price $12.54
Change -3.32%
About

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.00
Mean price target
2. Current target
$12.54
Latest analyst target
3. DCF / Fair value
$-20.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.54
Low
$14.00
High
$29.00
Mean
$22.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-06 main Baird Outperform → Outperform $20
2026-01-08 down Morgan Stanley Overweight → Equal-Weight $14
2025-11-24 main Baird Outperform → Outperform $14
2025-11-21 main RBC Capital Outperform → Outperform $22
2025-09-25 init Leerink Partners — → Outperform $20
2025-08-18 main Morgan Stanley Overweight → Overweight $21
2025-05-19 main Morgan Stanley Overweight → Overweight $20
2025-05-15 reit RBC Capital Outperform → Outperform $31
2025-03-13 init Jones Trading — → Buy $23
2025-03-07 main Baird Outperform → Outperform $16
2025-01-09 reit RBC Capital Outperform → Outperform $31
2024-11-07 main RBC Capital Outperform → Outperform $31
2024-10-22 init Baird — → Outperform $32
2024-08-14 main RBC Capital Outperform → Outperform $32
2024-04-30 init RBC Capital — → Outperform $30
2024-04-30 init Stifel — → Buy $29
2024-04-30 init Morgan Stanley — → Overweight $25
News
RSS: Latest CTNM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-06 LORRAIN DANIEL S. PH.D. Officer — 4,170 $13.43 $56,014
2026-03-02 LORRAIN DANIEL S. PH.D. Officer — 4,170 $15.01 $62,585
2026-03-02 WATKINS TIMOTHY M.D. Officer — 3,611 $15.02 $54,220
2026-03-02 WATKINS TIMOTHY M.D. Officer — 3,611 $4.50 $16,250
2026-02-25 STENGONE CARMINE N Chief Executive Officer — 7,100 $16.02 $113,728
2026-02-25 STENGONE CARMINE N Chief Executive Officer — 7,100 $1.26 $8,946
2026-02-25 LORRAIN DANIEL S. PH.D. Officer — 8,124 $16.01 $130,164
2026-02-25 LORRAIN DANIEL S. PH.D. Officer — 8,124 $1.01 $8,205
2026-02-19 LORRAIN DANIEL S. PH.D. Officer — 100 $16.00 $1,600
2026-02-19 LORRAIN DANIEL S. PH.D. Officer — 100 $1.01 $101
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
50.00
0.00
Operating Revenue
0.00
0.00
-100.00%
50.00
0.00
Operating Expense
68.06
+33.73%
50.89
+50.03%
33.92
+49.31%
22.72
Research And Development
51.52
+34.10%
38.42
+39.20%
27.60
+63.39%
16.89
Selling General And Administration
16.54
+32.59%
12.47
+97.34%
6.32
+8.48%
5.83
General And Administrative Expense
16.54
+32.59%
12.47
+97.34%
6.32
+8.48%
5.83
Other Gand A
16.54
+32.59%
12.47
+97.34%
6.32
+8.48%
5.83
Total Expenses
68.06
+33.73%
50.89
+50.03%
33.92
+49.31%
22.72
Operating Income
-68.06
-33.73%
-50.89
-416.56%
16.08
+170.76%
-22.72
Total Operating Income As Reported
-68.06
-33.73%
-50.89
-216.56%
-16.08
+29.24%
-22.72
EBITDA
-67.74
-33.77%
-50.64
-314.81%
23.57
+200.16%
-23.54
Normalized EBITDA
-67.74
-34.05%
-50.53
-344.09%
20.70
+195.30%
-21.72
Reconciled Depreciation
0.32
+25.19%
0.26
+32.31%
0.20
-40.73%
0.33
EBIT
-68.06
-33.73%
-50.89
-317.70%
23.38
+197.96%
-23.86
Total Unusual Items
—
-0.11
-103.69%
2.87
+258.32%
-1.81
Total Unusual Items Excluding Goodwill
—
-0.11
-103.69%
2.87
+258.32%
-1.81
Special Income Charges
—
0.00
-100.00%
2.87
+257.79%
-1.82
Other Special Charges
—
—
-2.87
-257.79%
1.82
Net Income
-59.98
-41.93%
-42.26
-285.99%
22.72
+193.68%
-24.25
Pretax Income
-59.98
-41.93%
-42.26
-282.38%
23.17
+195.53%
-24.25
Net Non Operating Interest Income Expense
8.25
-7.40%
8.90
+102.48%
4.40
+1079.09%
0.37
Interest Expense Non Operating
—
0.00
-100.00%
0.21
-46.39%
0.39
Net Interest Income
8.25
-7.40%
8.90
+102.48%
4.40
+1079.09%
0.37
Interest Expense
—
0.00
-100.00%
0.21
-46.39%
0.39
Interest Income Non Operating
8.25
-7.40%
8.90
+93.33%
4.61
+505.26%
0.76
Interest Income
8.25
-7.40%
8.90
+93.33%
4.61
+505.26%
0.76
Other Income Expense
-0.17
+38.66%
-0.27
-109.98%
2.69
+241.40%
-1.91
Other Non Operating Income Expenses
-0.17
-1.23%
-0.16
+7.91%
-0.18
-92.39%
-0.09
Gain On Sale Of Security
—
-0.11
-2220.00%
0.01
+66.67%
0.00
Tax Provision
—
0.00
-100.00%
0.45
0.00
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
0.06
0.00
Net Income Including Noncontrolling Interests
-59.98
-41.93%
-42.26
-285.99%
22.72
+193.68%
-24.25
Net Income From Continuing Operation Net Minority Interest
-59.98
-41.93%
-42.26
-285.99%
22.72
+193.68%
-24.25
Net Income From Continuing And Discontinued Operation
-59.98
-41.93%
-42.26
-285.99%
22.72
+193.68%
-24.25
Net Income Continuous Operations
-59.98
-41.93%
-42.26
-285.99%
22.72
+193.68%
-24.25
Normalized Income
-59.98
-42.29%
-42.15
-311.78%
19.90
+188.70%
-22.44
Net Income Common Stockholders
-59.98
-41.93%
-42.26
-285.99%
22.72
+193.68%
-24.25
Diluted EPS
—
-2.18
-359.60%
0.84
+157.73%
-1.45
Basic EPS
—
-2.18
-359.60%
0.84
+157.73%
-1.45
Basic Average Shares
—
19.35
-28.47%
27.06
+62.26%
16.67
Diluted Average Shares
—
19.35
-28.47%
27.06
+52.34%
17.76
Diluted NI Availto Com Stockholders
-59.98
-41.93%
-42.26
-285.99%
22.72
+193.68%
-24.25
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
276.64
+29.97%
212.85
+63.24%
130.39
+157.50%
50.64
Current Assets
267.92
+29.81%
206.39
+61.61%
127.71
+163.90%
48.39
Cash Cash Equivalents And Short Term Investments
262.90
+28.39%
204.76
+63.56%
125.19
+165.01%
47.24
Cash And Cash Equivalents
75.60
+244.54%
21.94
+41.33%
15.53
+178.79%
5.57
Other Short Term Investments
187.29
+2.45%
182.82
+66.71%
109.66
+163.17%
41.67
Other Current Assets
5.02
+208.42%
1.63
-35.29%
2.52
+118.21%
1.15
Total Non Current Assets
8.72
+35.08%
6.46
+141.01%
2.68
+19.43%
2.24
Net PPE
8.47
+31.18%
6.46
+362.13%
1.40
-33.95%
2.12
Gross PPE
10.43
+27.64%
8.17
+184.38%
2.87
-15.35%
3.40
Accumulated Depreciation
-1.96
-14.33%
-1.72
-16.25%
-1.48
-15.39%
-1.28
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.30
+4.88%
0.29
+421.82%
0.06
+96.43%
0.03
Other Properties
9.95
+29.09%
7.71
+178.27%
2.77
-17.26%
3.35
Leases
0.18
+1.14%
0.17
+264.58%
0.05
+166.67%
0.02
Other Non Current Assets
0.26
+8433.33%
0.00
-99.77%
1.28
+894.57%
0.13
Total Liabilities Net Minority Interest
15.65
+5.90%
14.78
-92.55%
198.32
+37.87%
143.85
Current Liabilities
9.74
-2.31%
9.97
+81.87%
5.48
-27.36%
7.55
Payables And Accrued Expenses
2.61
-49.71%
5.18
+66.37%
3.12
+163.62%
1.18
Payables
1.02
-43.90%
1.81
+185.20%
0.64
+47.67%
0.43
Accounts Payable
1.02
-43.90%
1.81
+185.20%
0.64
+47.67%
0.43
Current Accrued Expenses
1.59
-52.83%
3.37
+35.95%
2.48
+229.92%
0.75
Pensionand Other Post Retirement Benefit Plans Current
4.80
+43.68%
3.34
+75.32%
1.90
+45.34%
1.31
Current Debt And Capital Lease Obligation
2.34
+61.23%
1.45
+212.93%
0.46
-90.83%
5.06
Current Debt
—
—
—
3.95
Other Current Borrowings
—
—
—
3.95
Current Capital Lease Obligation
2.34
+61.23%
1.45
+212.93%
0.46
-58.20%
1.11
Current Deferred Liabilities
—
—
—
0.00
Total Non Current Liabilities Net Minority Interest
5.91
+22.92%
4.81
-97.51%
192.84
+41.48%
136.30
Long Term Debt And Capital Lease Obligation
5.91
+22.92%
4.81
+4350.93%
0.11
-86.35%
0.79
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
5.91
+22.92%
4.81
+4350.93%
0.11
-86.35%
0.79
Other Non Current Liabilities
—
—
0.11
-96.36%
3.02
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
192.62
+45.39%
132.48
Stockholders Equity
260.99
+31.77%
198.07
+391.55%
-67.94
+27.12%
-93.21
Common Stock Equity
260.99
+31.77%
198.07
+391.55%
-67.94
+27.12%
-93.21
Capital Stock
0.04
+42.31%
0.03
+1200.00%
0.00
+0.00%
0.00
Common Stock
0.04
+42.31%
0.03
+1200.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
37.32
+44.35%
25.85
-4.44%
27.06
+0.00%
27.06
Ordinary Shares Number
37.32
+44.35%
25.85
-4.44%
27.06
+0.00%
27.06
Additional Paid In Capital
438.07
+38.91%
315.37
+4343.10%
7.10
+50.19%
4.73
Retained Earnings
-177.38
-51.09%
-117.40
-56.24%
-75.14
+23.22%
-97.86
Gains Losses Not Affecting Retained Earnings
0.26
+266.20%
0.07
-34.26%
0.11
+242.11%
-0.08
Other Equity Adjustments
0.26
+266.20%
0.07
-34.26%
0.11
+242.11%
-0.08
Total Equity Gross Minority Interest
260.99
+31.77%
198.07
+391.55%
-67.94
+27.12%
-93.21
Total Capitalization
260.99
+31.77%
198.07
+391.55%
-67.94
+27.12%
-93.21
Working Capital
258.17
+31.44%
196.41
+60.70%
122.22
+199.26%
40.84
Invested Capital
260.99
+31.77%
198.07
+391.55%
-67.94
+23.89%
-89.26
Total Debt
8.25
+31.81%
6.26
+994.23%
0.57
-90.22%
5.85
Net Debt
—
—
—
—
Capital Lease Obligations
8.25
+31.81%
6.26
+994.23%
0.57
-69.91%
1.90
Net Tangible Assets
260.99
+31.77%
198.07
+391.55%
-67.94
+27.12%
-93.21
Tangible Book Value
260.99
+31.77%
198.07
+391.55%
-67.94
+27.12%
-93.21
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-55.31
-68.40%
-32.84
-269.75%
19.35
+196.16%
-20.12
Cash Flow From Continuing Operating Activities
-55.31
-68.40%
-32.84
-269.75%
19.35
+196.16%
-20.12
Net Income From Continuing Operations
-59.98
-41.93%
-42.26
-285.99%
22.72
+193.68%
-24.25
Depreciation Amortization Depletion
0.32
+25.19%
0.26
+32.31%
0.20
-40.73%
0.33
Depreciation And Amortization
0.32
+25.19%
0.26
+32.31%
0.20
-40.73%
0.33
Other Non Cash Items
1.08
+23.85%
0.87
+141.52%
-2.10
-172.46%
2.90
Stock Based Compensation
10.04
+47.53%
6.80
+206.62%
2.22
+15.15%
1.93
Operating Gains Losses
0.06
-35.29%
0.09
+507.14%
0.01
+300.00%
-0.01
Gain Loss On Investment Securities
-0.01
-111.88%
0.10
+621.43%
0.01
+255.56%
-0.01
Gain Loss On Sale Of PPE
0.07
+518.75%
-0.02
0.00
-100.00%
0.00
Change In Working Capital
-6.04
-213.22%
5.33
+620.90%
-1.02
+19.18%
-1.27
Change In Prepaid Assets
-3.40
-482.86%
0.89
+169.46%
-1.28
-237.83%
-0.38
Change In Payables And Accrued Expense
-1.39
-140.21%
3.44
+116.06%
1.59
+2244.12%
0.07
Change In Accrued Expense
-0.52
-122.41%
2.30
+44.48%
1.59
+434.90%
0.30
Change In Payable
-0.87
-176.16%
1.14
—
-0.23
Change In Account Payable
-0.87
-176.16%
1.14
0.00
+100.00%
-0.23
Change In Other Current Assets
0.00
-99.68%
0.94
+13285.71%
0.01
+121.88%
-0.03
Change In Other Current Liabilities
-1.26
-2010.61%
0.07
+104.90%
-1.35
-45.73%
-0.93
Investing Cash Flow
-3.71
+94.68%
-69.74
-6.36%
-65.57
-394.04%
22.30
Cash Flow From Continuing Investing Activities
-3.71
+94.68%
-69.74
-6.36%
-65.57
-394.04%
22.30
Net PPE Purchase And Sale
-0.23
+53.24%
-0.49
-19.32%
-0.41
-250.85%
-0.12
Purchase Of PPE
-0.23
+55.06%
-0.51
-24.15%
-0.41
-250.85%
-0.12
Sale Of PPE
0.00
-100.00%
0.02
0.00
—
Capital Expenditure
-0.23
+55.06%
-0.51
-24.15%
-0.41
-250.85%
-0.12
Net Investment Purchase And Sale
-3.48
+94.97%
-69.25
-6.28%
-65.15
-390.65%
22.42
Purchase Of Investment
-162.50
+28.23%
-226.41
-59.59%
-141.87
-119.27%
-64.70
Sale Of Investment
159.02
+1.18%
157.16
+104.87%
76.71
-11.94%
87.12
Financing Cash Flow
112.69
+3.38%
109.00
+94.03%
56.18
+4633.98%
-1.24
Cash Flow From Continuing Financing Activities
112.69
+3.38%
109.00
+94.03%
56.18
+4633.98%
-1.24
Net Issuance Payments Of Debt
—
0.00
+100.00%
-3.75
-200.00%
-1.25
Repayment Of Debt
—
0.00
+100.00%
-3.75
-200.00%
-1.25
Long Term Debt Payments
—
0.00
+100.00%
-3.75
-200.00%
-1.25
Net Long Term Debt Issuance
—
0.00
+100.00%
-3.75
-200.00%
-1.25
Short Term Debt Payments
—
—
-3.75
-200.00%
-1.25
Net Short Term Debt Issuance
—
—
-3.75
-200.00%
-1.25
Net Common Stock Issuance
112.25
+3.74%
108.21
+386567.86%
-0.03
-600.00%
-0.00
Common Stock Payments
—
0.00
+100.00%
-0.03
-600.00%
-0.00
Repurchase Of Capital Stock
—
0.00
+100.00%
-0.03
-600.00%
-0.00
Proceeds From Stock Option Exercised
0.69
-13.16%
0.79
+396.86%
0.16
+960.00%
0.01
Net Other Financing Charges
-0.26
—
-0.34
—
Changes In Cash
53.66
+736.22%
6.42
-35.55%
9.96
+960.38%
0.94
Beginning Cash Position
21.94
+41.33%
15.53
+178.79%
5.57
+20.28%
4.63
End Cash Position
75.60
+244.54%
21.94
+41.33%
15.53
+178.79%
5.57
Free Cash Flow
-55.54
-66.50%
-33.36
-276.18%
18.93
+193.56%
-20.24
Interest Paid Supplemental Data
—
0.00
-100.00%
0.15
-33.33%
0.23
Income Tax Paid Supplemental Data
—
0.00
-100.00%
0.45
0.00
Amortization Of Securities
-0.79
+79.92%
-3.94
-47.29%
-2.67
-1161.51%
0.25
Common Stock Issuance
112.25
+3.74%
108.21
0.00
—
Issuance Of Capital Stock
112.25
+3.74%
108.21
+79.94%
60.14
0.00
Net Preferred Stock Issuance
—
0.00
-100.00%
60.14
0.00
Preferred Stock Issuance
—
0.00
-100.00%
60.14
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category